uniQure (NASDAQ:QURE) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its stake in uniQure (NASDAQ:QURE) by 9.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 468,357 shares of the biotechnology company’s stock after purchasing an additional 41,166 shares during the period. BNP Paribas Financial Markets owned about 0.96% of uniQure worth $8,271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of QURE. Franklin Resources Inc. acquired a new stake in shares of uniQure during the 3rd quarter worth about $7,360,000. FNY Investment Advisers LLC acquired a new stake in shares of uniQure during the 4th quarter worth about $88,000. Sanders Morris Harris LLC raised its position in shares of uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after acquiring an additional 34,034 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth about $437,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Trading Up 4.3%

Shares of QURE stock opened at $12.78 on Monday. The business’s 50 day moving average is $12.22 and its two-hundred day moving average is $12.13. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a market capitalization of $700.04 million, a P/E ratio of -2.58 and a beta of 0.10. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. Equities analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. This trade represents a 4.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now owns 155,168 shares in the company, valued at $1,756,501.76. This trade represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on QURE shares. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of uniQure in a research report on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Monday, April 21st. StockNews.com raised uniQure to a “sell” rating in a research report on Tuesday, March 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.